Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Goldman Sachs Downgrades Doximity to Sell, Raises Price Target to $64

Author: Benzinga Newsdesk | October 01, 2025 12:36pm
Goldman Sachs analyst David Roman downgrades Doximity (NYSE:DOCS) from Neutral to Sell and raises the price target from $57 to $64.

Posted In: DOCS

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist